$32.76
$83.95
bear $32.76
base $61.20
bull $83.95
margin of safety $42.00
market price* $62.99
Minerals Technologies mines, refines and engineers industrial minerals, principally bentonite clay, precipitated and ground calcium carbonate and talc, and sells them into a wide spread of uses. It reports in two parts of roughly equal size. Consumer & Specialties makes cat litter and other pet-care products, personal-care and fabric-care ingredients, bleaching earth used to purify edible oils, and precipitated calcium carbonate that paper and packaging mills use as a filler. That carbonate is usually made in satellite plants built inside the customer's mill under evergreen contracts that start at ten to fifteen years and are often extended when the plant is expanded. Engineered Solutions supplies bentonite-based foundry binders for metal casting, refractory products and services for steel mills, geosynthetic clay liners for landfills and containment, and environmental and well-services products. Revenue was $2.07 billion in 2025 and $1.10 billion in the first half of 2026, 7 percent higher than a year earlier, with Engineered Solutions up 9 percent in the second quarter on stronger US steel and Asian foundry demand while Consumer & Specialties slipped 1 percent. About 48 percent of sales come from outside the United States. The business earns its return from long-lived mineral reserves, from plants embedded in customers' sites that are awkward to replace, and from formulation know-how, not from any single patent. It is moderately cyclical: foundry and refractory volumes follow steel and casting output, and graphic paper is in long decline, partly offset by packaging and newer mills in Asia and India. How we measured earnings. We start from cash produced by operations, strip out swings in receivables, inventory, payables and taxes owed, and deduct stock compensation and the capital spending needed to keep current capacity running. Pension contributions, restructuring payments and a recurring outflow the company labels prepaid expenses and other are left in as real costs, because they recur almost every year rather than reversing. On that basis owner earnings over 2016 to 2025 ranged from $3.26 to $5.19 per share, with a middle value of about $4.53. Each year's cash-flow statement reconciled exactly to the reported figures. Because this valuation looks at the business before its lenders and then subtracts what it owes, we add back cash interest, which ran about $60 million a year in 2023 to 2025 (the company states interest paid approximated the $61.0 million incurred in 2025). That gives business cash flow ranging from roughly $5.4 to $6.5 per share, around $6.40 at the middle of the decade and about $5.30 to $5.50 on average over the last four years, when capital spending ran at $90 to $107 million against a ten-year average near $80 million and revenue did not grow. We use the full ten years because they span a complete cycle: the 2020 pandemic trough, the 2021 to 2022 inventory build that temporarily starved cash, and the soft industrial volumes of 2023 to 2025. But we lean toward the more recent years rather than the ten-year middle, because 2022 to 2025 includes a structurally heavier capital spending load and higher energy and freight costs that the company says it has not fully passed through. Our normal level is about $181 million a year of business cash flow, roughly $5.80 per share on 31.1 million diluted shares. In the most recently completed year, 2025, owner earnings fell about 28 percent from 2024 as capital spending rose to $107 million and taxes payable unwound. We assume no growth in year one of the base case: the first-half 2026 sales gain is real, but the second-quarter margin squeeze in Consumer & Specialties and the still-elevated capital budget ($50.3 million in the first half, a pace slightly above 2025) mean it has not yet shown up as more cash. The talc liability is the central issue. In October 2023 two subsidiaries, BMI Oldco (formerly Barretts Minerals) and Barretts Ventures Texas, filed for Chapter 11 to resolve claims that talc they sold contained asbestos. The company accrued $30 million in 2024 (a debtor-in-possession loan to Oldco it expects to lose), $215 million in early 2025 and a further $290 million in the second quarter of 2026, about $535 million in total, of which roughly $480 million appears to remain to be paid; the jump in other current liabilities on the July 2026 balance sheet, from $361 million to $614 million, is consistent with that. Most importantly, since our previous analysis the company has filed its own plan of reorganization, under which Minerals Technologies and its other non-bankrupt affiliates would contribute $450 million to a talc personal-injury trust in exchange for an injunction under Section 524(g) of the Bankruptcy Code channelling all current and future talc claims to that trust. This is the first time the company has put a number on its total exposure in a form that, if confirmed, ends it. It is not yet settled: the claimants' committee has fought the bankruptcy from the start, the plan asks the court to pause confirmation until the District Court rules on whether Oldco's talc actually contained harmful asbestos, and Pfizer, which agreed in 1992 to indemnify the company for talc sold before its IPO, is in mediation with the company over how far that indemnity reaches. Like the earlier accruals, these charges are non-cash today and are added back automatically when we measure earnings from operating cash. We therefore charge them once, as a separate obligation, rather than reducing every future year's earnings. Debt. At July 5, 2026 the company had about $965 million of borrowings: $575 million of 5.0 percent senior notes due July 2028, a secured term loan due 2031, and small amounts of short-term and other debt. Its $342 million of cash and $4 million of short-term investments are partly needed to operate a business in more than 30 countries; we treat about $246 million as surplus. It also has $32 million of outside owners' interests in partly owned subsidiaries whose cash flow we include in full, which we count with the debt along with roughly $38 million of unfunded pension obligations beyond current contributions. The 2028 notes matter: the credit agreement steps its own maturity forward to 91 days before the notes mature unless the notes are refinanced, so the company must refinance or repay them by spring 2028. At about three times business cash flow, the debt is serviceable, and cash interest paid of $37.4 million in the first half of 2026 sits well inside the cash the business produces. Base case. Business cash flow holds at about $181 million a year with no growth credited. We give no credit to new satellite plants, India and Asia expansion or the newer product lines promoted at the September 2026 investor day, because none of these is contracted in the filings, and over the past decade the company's own growth from satellites and acquisitions has been roughly offset by graphic-paper closures and lost refractory volumes; revenue in 2025 was only 16 percent above 2017 and owner earnings were lower. The amortisation of acquired intangibles is modest at about $11 million a year and the customer relationships it reflects largely renew, so we see no wasting asset that needs a declining path. The talc trust is funded at about $480 million, after the tax deduction the company should receive when it pays, around 2028. On those assumptions the business is worth about $3.02 billion; it owes about $789 million of net debt, minority interests and pension obligations plus about $325 million for the talc trust in today's money, roughly $1.11 billion in total, leaving about $1.90 billion, or about $61 per share. Bear case. Two evidenced risks are combined. First, a real industrial downturn. In 2020 revenue fell 11 percent; in 2009 the company's sales fell about 20 percent as steel and foundry volumes collapsed, and the refractory and foundry businesses are now a larger share than they were then. We model a 2009-style shock starting from a lower base of $163 million, the average of the last four years: business cash flow down 30 percent in the second year and 15 percent in the third, recovering to the lower base, then shrinking about 1.5 percent a year as graphic-paper capacity keeps closing in North America and Europe. Second, the talc trust costs materially more than the company's own $450 million offer, around $750 million paid in about three years, plus about $45 million of extra cost if the Pfizer indemnity is narrowed. Claimants have opposed the case throughout and open claims grew from 684 at the end of 2024 to 914 at the end of 2025, so a higher number is plausible. Even at the trough the business still earns roughly three times its cash interest, and the 2028 notes would most likely be refinanced at a higher rate rather than defaulted on. On those assumptions the business is worth about $2.33 billion against roughly $1.31 billion of obligations including the larger trust, leaving about $33 per share. Bull case. The first-half 2026 recovery holds and the company's demonstrated pricing pass-through on satellite contracts restores Consumer & Specialties margins, lifting business cash flow to about $205 million, the level of the 2016 to 2021 years, then growing about 1.5 percent a year as the satellite plants the company has been building in Asia and India over 2023 to 2025 contribute volume, a pace below its long-run record. The $450 million plan is confirmed roughly as filed and paid within about a year. The business is then worth about $3.72 billion against about $1.11 billion of obligations, leaving about $84 per share. The margin of safety price. We are reasonably sure of the operating earnings level: ten years of reconciled cash flow, no year with negative owner earnings, and a business that kept generating $190 to $240 million of operating cash even in 2020 and while funding the talc case. We are much less sure of the talc number, but the company's own plan now gives a figure to measure against, $450 million, and the bear case allows for two thirds more than that. The worst plausible outcome no case fully models is a court allowing claimants to reach the parent company directly, outside the bankruptcy, with no cap; the structure of the business, with hard mineral reserves, embedded customer plants, moderate debt and no single customer large enough to sink it, would most likely survive even that through a larger, longer payment stream, but shareholders would bear it. If we are wrong about the two or three things most likely to go wrong, the trust cost, a deeper industrial cycle, and a 2028 refinancing on poor terms, the shares are worth roughly the low $30s. Over the holding period, the business pays a small dividend of about $0.48 a year and generates enough cash to fund the trust over a few years without new equity. The margin-of-safety price is $42. At that price the bear case, which already assumes a 2009-style downturn and a trust far above the company's own offer, still leaves the shares worth only about a quarter less, while confirmation of the plan at or near $450 million plus a normal year of earnings would put value in the high $50s to low $60s within two to three years, which implies well above a 20 percent annual return. Above the low $40s the estimate depends too heavily on the talc case resolving favourably. What changed since our previous analysis. The company filed its own plan of reorganization proposing $450 million from Minerals Technologies and its affiliates to fund a talc trust with a channelling injunction. Previously there was no number from the company at all and the accrual had no visible ceiling, so we required a confirmed plan before naming any margin-of-safety price. The filed plan does not end the matter, but it gives a concrete company-backed figure against which to size the risk, so we now name a margin of safety price without that condition and instead carry a much larger trust cost in the bear case. We also lowered our view of normal earnings toward the last four years, because the heavier capital spending since 2022 has persisted for four years rather than reversing, and we no longer credit growth from new satellite plants in the base case, since none is under contract in the filings. Those changes lower the base and bull values, while the filed plan supports a firmer view of the downside. The previous figures were built on a different basis and are not directly comparable. What could not be reconciled. The second-quarter 2026 10-Q text was not available to us in full, so the exact remaining talc accrual balance and the split of the $450 million between cash and other forms are estimated from the balance sheet and the company's release rather than read from the note.